ISHLT Welcomes Jeffrey Teuteberg, MD, as New Board President
Addison, Texas – June 5, 2018 – Dr. Jeffrey Teuteberg, Associate Professor of Medicine and Section Chief of Heart Failure, Cardiac Transplantation, and Mechanical Circulatory Support at the Stanford School of Medicine, has been elected to a one-year term as president of the International Society of Heart and Lung Transplantation (ISHLT).
“I’m honored to serve the ISHLT as president and work with Society members to advance the care of our patients and to extend to the impact of the Society across the globe,” said Dr. Teuteberg, who’s been a member of ISHLT since 2004.
The ISHLT is the world’s largest multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies
Dr. Teuteberg joined the Stanford faculty in 2017, after spending 13 years at the University of Pittsburgh Medical Center. His clinical research interests focus on cardiac transplantation and mechanical circulatory support.
“With the Society’s continued growth, diverse membership and global footprint, we will work to focus our strategic goals to provide value to our membership, improve the reach of the Society and assure that the organization can effectively and efficiently support our mission,” he said.
Dr. Teuteberg graduated from the University of Chicago, Pritzker School of Medicine, in 1992 and remained at the University of Chicago for his internal medicine residency, after which he spent a year as the chief medical resident, and general cardiovascular fellowship. Dr. Teuteberg received his heart failure and cardiac transplant training at Brigham and Women's Hospital in Boston. He received board certification in advanced heart failure and transplant cardiology from the American Board of Internal Medicine in 2010.
The ISHLT is a not-for-profit, multidisciplinary, professional organization dedicated to improving the care of patients with advanced heart or lung disease through transplantation, mechanical support and innovative therapies. With more than 3,000 members in more than 45 countries, ISHLT is the world’s largest organization dedicated to the research, education and advocacy of end-stage heart and lung disease. ISHLT members represent more than 15 different professional disciplines. For more information, visit www.ishlt.org.